Posters
from the 12th European AIDS Conference Available on HIVandHepatitis.com
 |
 |
 |
 |
 |
 |
 |
| SUMMARY:
The
12th European AIDS Conference, sponsored by the
European AIDS Clinical Society (EACS), took place
November 11-14 in Cologne, Germany. The major
annual conference focused on HIV/AIDS in Europe,
the meeting included numerous presentations on
approved and investigational HIV therapies, management
of HIV-associated complications and drug side
effects, and basic science about the virus and
how it affects the body. |
|
 |
 |
 |
 |
 |
 |
 |
HIV
and Hepatitis.com features a library of posters
and slides from the EACS conference provided by study investigators
and pharmaceutical companies. The first set of posters covers
the protease inhibitors lopinavir/ritonavir
(Kaletra) and darunavir
(Prezista), the recently approved non-nucleoside
reverse transcriptase inhibitor (NNRTI) etravirine
(Intelence), and the experimental NNRTI rilpivirine
(TMC278).
Other
researchers and companies are welcome to send additional
posters to be added to the library.
In
upcoming issues, HIV
and Hepatitis.com will be providing in-depth
coverage of some of the key conference presentations, including
data on boosted protease inhibitor monotherapy and comparative
toxicities of abacavir (Ziagen, also in the Epzicom coformulation)
and tenofovir (Viread, also in the Truvada and Atripla coformulations).
HIV
and AIDS
- Library of Slides and Posters |
|
|
Resistance
Implications of 96 Weeks of Treatment with Once- (QD)
or Twice- (BID) Daily Lopinavir/ritonavir
(LPV/r) with Tenofovir DF (TDF) and Emtricitabine (FTC)
in Antiretroviral (ARV)-naïve Subjects Daniel E.
Cohen, Martin S. King, Christian T.
D Cohen and others. EACS 2009.
|
 |
Improved
Treatment Compliance with Once-Daily (QD) Compared to
Twice-Daily (BID) Lopinavir/ritonavir
(LPV/r) in HIV-1-Infected, Antiretroviral-Experienced
Subjects
M King and others. EACS 2009.
|
|
Impact
of Baseline Resistance on Virologic Outcome with Once-Daily
(QD) or Twice-Daily (BID) Lopinavir/ritonavir
(LPV/r) through 48 Weeks of Combination Antiretroviral
Therapy in Treatment-Experienced, HIV-1-Infected Subjects
M King and others. EACS 2009.
|
|
Simplifi
ed Antiretroviral Therapy in Special Populations: Clinical
Outcomesn at Week 48 of Lopinavir/ritonavir
(LPV/r) Tablet Dosed Once Daily (QD) or Twice
Daily (BID), Administered with .2 Nucleoside Reverse
Transcriptase Inhibitors (NRTIs) in Antiretroviral-experienced
Subjects, Analyzed by Gender, Age, Race, Ethnicity,
and Hepatitis Co-infection Status (Study M06-802)
I Gaultier and others. EACS 2009.
|
|
Pharmacokinetic
interaction study between TMC278,
an NNRTI, and the contraceptives norethindrone
plus ethinylestradiol
H
Crauwels and others. EACS 2009. |
|
Absence
of a teratogenic potential from a novel next-generation
NNRTI, TMC278
M Desmidt and others. EACS 2009.
|
|
Absorption,
metabolism and excretion of TMC278,
an NNRTI, after a single oral dose of 150mg in healthy
male volunteers
S Lachau-Durand and others. EACS
2009. |
|
TMC278
25mg qd has no effect on corrected QT interval in a
study in HIV-negative volunteers
S Vanveggel and others. EACS 2009.
|
|
Pharmacokinetic
interaction between etravirine
and lopinavir/ritonavir in HIV-negative volunteers
M Schöller-Gyüre and
others. EACS 2009. |
|
Etravirine
demonstrates a favourable safety and tolerability profile
versus placebo irrespective of hepatitis co-infection:
Week 96 analysis from the DUET trials
B Clotet and others. EACS 2009.
|
|
Etravirine
demonstrates a favourable safety and tolerability profile:
pooled 96-week results from the Phase III DUET trials
P Girard and others. EACS 2009.
|
|
Safety
and pharmacokinetics of etravirine
in pregnant HIV-infected women
P Izurieta and others. EACS 2009.
|
|
Comparative
regimen durability and discontinuation reasons among
3-class experienced patients
in a US clinical cohort
J Willig and others. EACS 2009.
|
|
Cost-effectiveness
of current treatment options in treatment-resistant
HIV/AIDS patients in the German setting
L Annemans and others. EACS 2009.
|
|
The
economic impact
of national particularities in the healthcare system
– calculation for hospital-related costs from pooled
DUET trials by German diagnosis-related groups
M Stoll and others. EACS 2009.
|
11/17/09
Source
12th
European AIDS Conference. Cologne, Germany. November
11-14.
|
